1,2-二氨基(4-氯苄基)乙烷 | 104907-20-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,2-二氨基(4-氯苄基)乙烷
• 英文名称: 1,2-diamino(4-chlorobenzyl)ethane
• 英文别名: 1,2-Diamino-3-(4-chlorophenyl)propane；3-(4-chlorophenyl)propane-1,2-diamine
• CAS: 104907-20-2
• 化学式: C₉H₁₃ClN₂
• 分子量: 184.669
• InChiKey: DXJPJHDQAWNQLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  potassium tetrachloroplatinate(II) 、 1,2-二氨基(4-氯苄基)乙烷 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 [1,2-diamino(4-chlorobenzyl)ethane](dichloro)platinum(II)
  参考文献：
  名称：

  New porphyrin platinum conjugates for the cytostatic and photodynamic tumor therapy

  摘要：

  The combination of a porphyrin system and a platinum fragment in the same molecule should not only result in the additivity of the photodynamic activity of the porphyrin and the cytostatic activity of the platinum, but also in the enrichment of the porphyrin platinum conjugate in tumors, which platinum compounds alone do not show. New porphyrin platinum conjugates were obtained from the platinum complexes of a series of 1,2-diamines and hematoporphyrin or 13,17-bis(2-carboxyethyl)-3,8-bis [1-(ethyleneglycolmonoethylether)oxvethyl]-2,7,12,18-tetramethylporphin. The 1,2-diamines were synthesized starting from the corresponding stilbenes via 1,2-diazides. The new platinum porphyrin conjugates showed promising antitumor activity in tests with the mammary carcinoma cell line MDA-MB-231. (C) 2003 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0020-1693(02)01490-1
• 作为产物：
  描述：

  DL-4-氯苯丙氨酸 在 lithium aluminium tetrahydride 、 氯化亚砜 、 氨 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 135.0h， 生成 1,2-二氨基(4-氯苄基)乙烷
  参考文献：
  名称：

  Brunner; Kroiss; Schmidt, European Journal of Medicinal Chemistry, 1986, vol. 21, # 4, p. 333 - 338

  摘要：

  DOI：

文献信息

• 4-IMIDAZOLINES
  申请人：Galley Guido

  公开号：US20090012138A1

  公开（公告）日：2009-01-08

  The present invention relates to compounds of formula wherein R 1 , R 2 , X, Y and Ar are as defined herein and to their pharmaceutically active salts, with the exclusion of the racemic compound 4-benzyl-4,5-dihydro-1H-imidazole or its tautomer (CAS 131548-83-9). Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中R1，R2，X，Y和Ar如此定义，并且它们的药物活性盐，但排除外消旋化合物4-苄基-4,5-二氢-1H-咪唑或其互变异构体（CAS 131548-83-9）。式I的化合物具有良好的迹胺相关受体（TAARs）亲和力，尤其是对TAAR1，可用于治疗抑郁症，焦虑症，双相情感障碍，注意力缺陷多动障碍（ADHD），与压力相关的障碍，精神障碍，如精神分裂症，神经疾病，如帕金森病，神经退行性疾病，如阿尔茨海默病，癫痫，偏头痛，高血压，物质滥用和代谢性疾病，如进食障碍，糖尿病，糖尿病并发症，肥胖症，脂质代谢异常，能量消耗和吸收障碍，体温稳态障碍和功能障碍，睡眠和昼夜节律障碍，以及心血管疾病。
• [EN] 4-IMIDAZOLINES AND THEIR USE AS ANTIDEPRESSANTS<br/>[FR] 4-IMIDAZOLINES ET LEUR UTILISATION COMME ANTIDÉPRESSEURS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009003867A1

  公开（公告）日：2009-01-08

  The present invention relates to compounds of formula (I) wherein R1 is hydrogen, halogen or lower alkyl; R2 is hydrogen or amino; X-Y is -(CH2)n-, N(R)-CH2-, -O-CH2- or -S-CH2-; Ar is phenyl or naphthyl; n is 1 or 2; R is hydrogen or lower alkyl; and to their pharmaceutically active salts, with the exclusion of the racemic compound 4-benzyl-4,5-dihydro-lH-imidazole or its tautomer (CAS 131548-83-9). It has been found that the compounds of formula (I) have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式(I)的化合物，其中R1是氢，卤素或较低的烷基; R2是氢或氨基; X-Y是-(CH2)n-，N(R)- -，-O- -或-S- -; Ar是苯基或萘基; n为1或2; R是氢或较低的烷基; 以及它们的药物活性盐，排除了外消旋化合物4-苄基-4,5-二氢-1H-咪唑或其互变异构体（CAS 131548-83-9）。发现式(I)的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神障碍如精神分裂症、神经疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢障碍如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病。
• Tumor retarding (1-benzyl-ethylenediamine)-platin (II)-complexes
  申请人：ASTA-Werke Aktiengesellschaft Chemische Fabrik

  公开号：US04704464A1

  公开（公告）日：1987-11-03

  There are described (1-benzylethylenediamine)-platin(II)-complexes of the general formula: ##STR1## wherein the radicals R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are the same or different and are hydrogen, a C.sub.1 -C.sub.6 -alkyl group, a benzyl group, or a phenylethyl group, and B is a thienyl radical, an indolyl radical, an imidazolyl radical, or a phenyl radical substituted by the radicals R.sub.5, R.sub.6, an R.sub.7 which are the same or different and are hydrogen, halogen, trihalomethyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy, phenoxy, benzyloxy, C.sub.1 -C.sub.6 -alkanoyloxy, benzoyloxy, C.sub.1 -C.sub.6 -alkanesulfonyloxy, carboxy, C.sub.1 -C.sub.6 -carbalkoxy, cyano, aminocarboxyl, aminocarbonyl, which contains one or two C.sub.1 -C.sub.6 -alkyl radicals, C.sub.1 -C.sub.6 -alkylcarbonyl, nitro, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino, (C.sub.1 -C.sub.6 -alkyl).sub.3 N.sup.+, C.sub.1 -C.sub.6 -alkanoylamino, C.sub.1 -C.sub.6 -alkyl-C.sub.1 -C.sub.6 -alkanoylamino, C.sub.1 -C.sub.6 -alkanesulfonylamino, C.sub.1 -C.sub.6 -alkyl-C.sub.1 -C.sub.6 -alkanesulfonylamino, aminosulfonyl, aminosulfonyl which contains one or two C.sub.1 -C.sub.6 -alkyl radicals, C.sub.1 -C.sub.6 -alkoxysulfonyl (--SO.sub.2 --O--C.sub.1 --C.sub.6 -alkyl), sulfo (--SO.sub.3 H) or C.sub.1 -C.sub.6 -alkanesulfonyl and two of these groups can be the methylenedioxy group and X is the equivalent of a physiologically compatible anion, as well as optionally their salts with physiologically compatible cations and anions and process of their production.

  该专利描述了一般式为：##STR1##的（1-苄基乙二胺）-铂（II）-配合物，其中基团R.sub.1、R.sub.2、R.sub.3和R.sub.4相同或不同，可以是氢、C.sub.1-C.sub.6烷基、苄基或苯乙基基团；B是噻吩基团、吲哚基团、咪唑基团或苯基基团，该苯基基团被基团R.sub.5、R.sub.6、R.sub.7取代，这些基团相同或不同，可以是氢、卤素、三卤甲基、C.sub.1-C.sub.6烷基、羟基、C.sub.1-C.sub.6烷氧基、苯氧基、苄氧基、C.sub.1-C.sub.6酰氧基、苯甲酰氧基、C.sub.1-C.sub.6烷磺酰氧基、羧基、C.sub.1-C.sub.6羧烷氧基、氰基、氨基羧基、氨基甲酰基，其中包含一个或两个C.sub.1-C.sub.6烷基基团、C.sub.1-C.sub.6烷基羧酰基、硝基、氨基、C.sub.1-C.sub.6烷基氨基、二C.sub.1-C.sub.6烷基氨基、（C.sub.1-C.sub.6烷基）.sub.3 N.sup. +、C.sub.1-C.sub.6烷基酰胺基、C.sub.1-C.sub.6烷基-C.sub.1-C.sub.6烷基酰胺基、C.sub.1-C.sub.6烷基磺酰胺基、C.sub.1-C.sub.6烷基-C.sub.1-C.sub.6烷基磺酰胺基、氨基磺酰基、含有一个或两个C.sub.1-C.sub.6烷基基团的氨基磺酰基、C.sub.1-C.sub.6烷氧基磺酰基（-SO.sub.2-O-C.sub.1-C.sub.6烷基）、磺酸（-SO.sub.3 H）或C.sub.1-C.sub.6烷基磺酰基，其中两个基团可以是亚甲二氧基基团，X是生理兼容性阴离子的等效物，以及它们与生理兼容阳离子和阴离子的盐和生产过程（翻译结果仅供参考）。
• Tumorhemmende (1-Arylmethyl-ethylendiamin)-platin(II)-Komplexe
  申请人：ASTA Pharma AG

  公开号：EP0193083A1

  公开（公告）日：1986-09-03

  Tumorhemmende (1-Benzyl-ethylendiamin)-platin (II)-Komplexe der allgemeinen Formel worin die Reste R1, R2, R3 und R4 gleich oder verschieden sind und Wasserstoff, eine C1 -C6-Alkylgruppe, eine Benzylgruppe oder eine Phenylethylgruppe bedeuten, und B ein Thienylrest, ein Indolylrest, ein Imidazolylrest oder ein durch die Reste R5, R6 und R7 substituierter Phenylrest ist und die Reste R5, R6 und R7 gleich oder verschieden sind und Wasserstoff, Halogen, Trihalogenmethyl, C1-C6-Alkyl, Hydroxy, C1-C6-Alkoxy, Phenoxy, Benzyloxy, C1-C6-Alkanoyl- oxy, Benzoyloxy, C1-C6-Alkansulfonyloxy, Carboxy, C1-C6-Carbalkoxy, Cyano, Aminocarbonyl, Aminocarbonyl, welches einen oder zwei C1-C6-Alkylreste enthält, C1-C6-Alkylcarbonyl, Nitro, Amino, C1-C6-Alkylamino, Di-C1-C6- alkylamino, (C1-C6-Alkyl)3N⊕,C1-C6-Alkanoylamino, C1-C6-Alkyl-C1-C6-alkanoylamino, C1-C6-Alkansulfonylamino, C1-C6-Alkyl-C1-C6-alkansulfonylamino, Aminosulfonyl, Aminosulfonyl, weiches einen oder zwei C1-C6-Alkylreste enthält, C1-C6-Alkoxyxulfonyl (-SO2O-C1-C6-Alkyl), Sulfo (-S03H) oder C1-C6-Alkansulfonyl bedeuten und zwei dieser Reste auch die Methylendioxygruppe sein können und X für das Äquivalent eines physiologisch verträglichen Anions steht, sowie gegebenenfalls deren Salze mit physiologisch verträglichen Kationen oder Anionen und deren Herstellung.

  通式为(1-苄基乙二胺)-铂(II)的肿瘤抑制络合物 其中，基 R1、R2、R3 和 R4 相同或不同，并且是氢、C1-C6-烷基、苄基或苯乙基；B 是噻吩基、吲哚基、咪唑基或苯基，被基 R5、R6 和 R7 取代，并且基 R5、R6 和 R7 相同或不同，并且是氢、卤素、三卤甲基、R6和R7相同或不同，并且是氢、卤素、三卤甲基、C1-C6烷基、羟基、C1-C6烷氧基、苯氧基、苄氧基、C1-C6烷酰氧基、苯甲酰氧基、C1-C6烷磺酰氧基、羧基、C1-C6烷氧基、氰基、氨基羰基、含有一个或两个C1-C6烷基的氨基羰基、C1-C6-烷基羰基、硝基、氨基、C1-C6-烷基氨基、二-C1-C6-烷基氨基、(C1-C6-烷基)3N⊕、C1-C6-烷酰基氨基、C1-C6-烷基-C1-C6-烷酰基氨基、C1-C6-烷磺酰基氨基、C1-C6-烷基-C1-C6-烷磺酰氨基、氨基磺酰基、氨基磺酰基、含有一个或两个 C1-C6 烷基的软基、C1-C6-烷氧基磺酰基（-SO2O-C1-C6-烷基）、磺酰基（-S03H）或 C1-C6- 烷磺酰基，其中两个基团也可以是亚甲基二氧基，X 代表生理上可耐受的阴离子的等价物，也可以是其与生理上可耐受的阳离子或阴离子的盐及其制备方法。
• ——
  作者：BRUNNER H.、 SCHONENBERGER H.、 SCHMIDT M.、 HOLZINGER U.、 UNGER G.、 ENGEL J+

  DOI：——

  日期：——